Protection Effect of Xinmailong Injection in Treating Breast Cancer Patients with Myocardial Damage Caused by Sequential Chemotherapy of Trastuzumab and Anthracyclines

YAO Tie-zhu; XU Zhi-hong; MA Jing-tao; ZHANG Ning; GAO Wei; ZHANG Shou-de; GUO Yong

doi:10.13422/j.cnki.syfjx.2016060154

您当前的位置：

首页 >

文章列表页 >

Protection Effect of Xinmailong Injection in Treating Breast Cancer Patients with Myocardial Damage Caused by Sequential Chemotherapy of Trastuzumab and Anthracyclines

更新时间：2024-01-04

- Protection Effect of Xinmailong Injection in Treating Breast Cancer Patients with Myocardial Damage Caused by Sequential Chemotherapy of Trastuzumab and Anthracyclines
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 22, Issue 6, Pages: 154-158(2016)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2016060154
  CLC： R737.9
- Published：2016
- 稿件说明：
移动端阅览
YAO Tie-zhu, XU Zhi-hong, MA Jing-tao, et al. Protection Effect of Xinmailong Injection in Treating Breast Cancer Patients with Myocardial Damage Caused by Sequential Chemotherapy of Trastuzumab and Anthracyclines[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(6): 154-158.
DOI：

YAO Tie-zhu, XU Zhi-hong, MA Jing-tao, et al. Protection Effect of Xinmailong Injection in Treating Breast Cancer Patients with Myocardial Damage Caused by Sequential Chemotherapy of Trastuzumab and Anthracyclines[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(6): 154-158. DOI： 10.13422/j.cnki.syfjx.2016060154.

摘要

目的: 探讨心脉隆注射液对蒽环类药物、曲妥珠单抗序贯治疗乳腺癌患者致心脏毒性的保护作用以及对血清白细胞介素(IL)-6和肿瘤坏死因子-α(TNF-α)含量的影响。方法: 选择河北医科大学第四医院收治的乳腺癌患者60例

随机分为对照组和治疗组各30例;对照组应用曲妥珠单抗和蒽环类药物序贯治疗

吡柔比星60 mg·m-2;表阿霉素 60 mg·m-2;曲妥珠单抗在蒽环类药物结束后开始下一疗程

首次剂量为8 mg·kg-1

此后6 mg·kg-1治疗;1周期/3周

共6周期

1次/周期。治疗组在对照组治疗基础上给予心脉隆注射液

于化疗前1 d开始给予

2支/次

7次/周期

化疗结束后继续治疗1周。比较两组中医临床症状评分

血清肌钙蛋白I(cTnI)和心型游离脂肪酸结合蛋白(H-FABP)含量;检测两组治疗前后血液流变学变化

血清IL-6和TNF-α含量。结果: 化疗结束时和化疗后1周

治疗组患者中医临床症状评分

血清cTnI

H-FABP

全血高、中、低切黏度

血浆黏度

血清TNF-α

IL-6均显著低于对照组(P<0.01)。结论: 心脉隆注射液针对蒽环类药物、曲妥珠单抗序贯治疗乳腺癌致心脏毒性

可明显改善患者临床症状和心肌损伤

降低血液黏度

抑制血清IL-6

TNF-α水平。

Abstract

Objective: To discuss the protection effect of Xinmailong injection in treating breast cancer patients with myocardial damage caused by sequential chemotherapy of trastuzumab and anthracyclines and investigate its effect on serum levels of interleukin-6 (IL-6) and tumor necrosis factor (TNF-α). Method: Sixty breast cancer patients in our hospital were randomly divided into control group (30 cases) and treatment group (30 cases) with reference to digital table method. Patients of control group were treated with sequential chemotherapy of trastuzumab (after the periods of anthracyclines with first-dose of 8 mg·kg-1 and 6 mg·kg-1 hereafter) and anthracyclines (pirarubicin

60 mg·m-2 and pharmorubicin

60 mg·m-2)

1 course/3 weeks

1 time/course

6 courses in total. Patients of treatment group were also given with Xinmailong injection based on the treatment of control group from one day before chemotherapy to one week after chemotherapy (2 injections/time

7times/course). The symptomatic scores of traditional Chinese medicine (TCM)

serum troponinI(cTnI) and heart-type fatty acid-binding protein (H-FABP) in two groups were compared. Changes of hemorheology

serum IL-6 and TNF-α were detected before and after treatment in two groups. Result: The symptomatic scores of TCM

serum levels of cTnI and H-FABP in treatment group were significantly lower than those in control group at the ending of chemotherapy and 1 week after chemotherapy (P<0.01). Blood viscosities of high shearrate

middle shearrate and low shearrate

plasma viscosity

serum levels of IL-6 and TNF-α in treatment group were significantly lower than those in control group at the ending of chemotherapy and 1 week after chemotherapy

with statistically significant difference (P<0.01). Conclusion: Xinmailong injection could effectively improve the clinical symptoms and myocardial damages in treating breast cancer patients with myocardial damage caused by sequential chemotherapy of trastuzumab and anthracyclines. The mechanism may be associated with decreasing blood viscosity and inhibiting expressions of serum IL-6 and TNF-α.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploring Mechanism of Breast Cancer Prevention by Liuwei Dihuangwan， Erzhiwan and Zuoguiwan Based on Macrophage Phagocytosis

Screening of Anti-breast Cancer Active Ingredients in Famous Classical Formula Yanghetang

Intervention of Breast Cancer by Regulating Wnt/β-catenin Signaling Pathway with Traditional Chinese Medicine： A Review

Role and Mechanism of Cucurbitacin B in Suppressing Proliferation of Breast Cancer 4T1 Cells via Inducing Ferroptosis

Characteristic Analysis of Effective Components and Compounds of TCM for Prevention and Treatment of Breast Cancer Based on Wnt/β-catenin Signaling Pathway Targeting

Related Author

ZHENG Lixiang

CHEN Yishan

QUAN Wei

ZHONG Youbao

GUO Zifeng

SU Sijia

ZHAO Xinyu

ZHOU Jingna

Related Institution

Jiangxi University of Chinese Medicine

Dongfang Hospital， Beijing University of Chinese Medicine

The First Affiliated Hospital of Heilongjiang University of TCM

The First Clinical Medical College of Heilongjiang University of Traditional Chinese Medicine （TCM）

School of Chinese Material Medica， Beijing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰